



## Greenhouse Gas Verification Statement Number VOL.INV.PRS.UK.0714.2020

The inventory of Greenhouse Gas emissions in the period  
01/01/2020 – 31/12/2020 for

### Alexion Pharmaceuticals

College Business and Technology Park  
Blandchartstown  
Dublin 15

has been verified in accordance with ISO 14064-3:2006,  
to represent on a market-based approach a total amount of:

**11,264 tCO<sub>2</sub>e**

#### For the following activities

Manufacture of pharmaceutical products

Lead Assessor: Lisa Gibson

Technical Reviewer: Paulomi Raythatha

Authorised by:

*Pamela Chadwick*  
*Business Manager*  
*SGS United Kingdom Ltd*

#### Verification Statement Date 17<sup>th</sup> March 2021

This Statement is not valid without the full verification scope, objectives, criteria and conclusion available  
on pages 2 to 4 of this Statement.

SGS United Kingdom Ltd

SGS House, 217-221 London Road, Camberley, Surrey GU15 3EY Tel +44 (0)1276 697677 Fax +44 (0)1276 697700  
Climate Change Programme ukclimatechange@sgs.com www.sgs.com

Member of SGS Group  
(Société Générale de Surveillance)



## **Schedule Accompanying Greenhouse Gas Verification Statement Number VOL.INV.PRS.UK.0714.2020**

### **Brief Description of Verification Process**

SGS has been contracted by Alexion Pharmaceuticals for the verification of direct and indirect carbon dioxide (CO<sub>2</sub>) equivalent emissions as provided by Alexion Pharmaceuticals, College Business and Technology Park, Blanchartstown, Dublin 15 in their Greenhouse Gas Emissions Report covering CO<sub>2</sub> equivalent emissions.

### **Roles and responsibilities**

The management of Alexion Pharmaceuticals is responsible for the organization's GHG information system, the development and maintenance of records and reporting procedures in accordance with that system, including the calculation and determination of GHG emissions information and the reported GHG emissions.

It is SGS' responsibility to express an independent GHG verification opinion on the emissions as provided in the Alexion Pharma International Operations UC GHG Assertion for the period 01/01/2020 – 31/12/2020.

SGS conducted a third-party verification following the requirements of ISO 14064-3:2006 of the provided CO<sub>2</sub> equivalent assertion in the period January to March 2021.

The assessment included a desk review and site visit at the Dublin facility. The verification was based on the verification scope, objectives and criteria as agreed between Alexion Pharmaceuticals and SGS on 11/12/2020.

### **Level of Assurance**

The level of assurance agreed is *reasonable*

### **Scope**

Alexion Pharmaceuticals has commissioned an independent verification by SGS of reported CO<sub>2</sub> equivalent emissions arising from their activities, to establish conformance with the requirements of ISO 14064-3 within the scope of the verification as outlined below. Data and information supporting the CO<sub>2</sub> equivalent assertion were historical in nature and proven by evidence.

This engagement covers verification of emissions from anthropogenic sources of greenhouse gases included within the organization's boundary and meets the requirements of ISO 14064-3.

- The organizational boundary was established following the operational control approach.
- Title or description of activities: Manufacture of Pharmaceutical products
- Location/boundary of the activities: Facilities in Dublin and Athlone in Ireland, Bogart and New Haven facilities within the US.
- GHG sources, sinks and/or reservoirs included:
  - Scope 1 - stationary combustion only
  - Scope 2 – purchased electricity (market and location based);



- Types of GHGs included: CO<sub>2</sub>, N<sub>2</sub>O, CH<sub>4</sub>,
- Directed actions: none
- GHG information for the following period was verified: Calendar Year 2020.
- Intended user of the verification statement: internal, customers, general public.

**Objective**

The purpose of this verification exercise was, by review of objective evidence, to independently review:

- Whether the CO<sub>2</sub> equivalent emissions are as declared by the organization's CO<sub>2</sub> equivalent assertion
- That the data reported are accurate, complete, consistent, transparent and free of material error or omission.

**Criteria**

Criteria against which the verification assessment is undertaken are a methodology defined by of Alexion Pharmaceuticals based on the requirements of the GHG Protocol, Corporate Accounting and Reporting Standard.

**Materiality**

The materiality required of the verification was considered by SGS to be below 5%, based on the needs of the intended user of the GHG Assertion

**Conclusion**

The GHG assertion of Alexion Pharmaceuticals for the 2020 calendar year, disclosing emissions of 11,264 metric tonnes of CO<sub>2</sub> equivalent (market-based approach) are verified by SGS to a reasonable level of assurance, consistent with the agreed verification scope, objectives and criteria.

The following data sets were also verified:

Scope 1 emissions (combustion emissions only) 6,895 Tonnes CO<sub>2</sub>e

Scope 2 emissions (market-based) 4,369 Tonnes CO<sub>2</sub>e

Scope 2 emissions (location-based) 11,651 Tonnes CO<sub>2</sub>e –

Water consumption: 254,808 megalitres

Waste generation:

Hazardous waste 189.8 metric tonnes

Non-Hazardous waste 451.1 metric tonnes

Recycled waste 350.3 metric tonnes

Energy Consumption Renewable 80.66 TJ

Energy Consumption Non-renewable 183.22 TJ

Total energy Consumption 263.88 TJ

SGS' approach is risk-based, drawing on an understanding of the risks associated with modeling GHG emission information and the controls in place to mitigate these risks. Our examination included assessment, on a sample basis, of evidence relevant to the voluntary reporting of emission information.



SGS concludes with reasonable assurance that the presented CO<sub>2</sub> equivalent assertion is materially correct and is a fair representation of the CO<sub>2</sub> equivalent data and information.

We planned and performed our work to obtain the information, explanations and evidence that we considered necessary to provide a reasonable level of assurance that the CO<sub>2</sub> equivalent emissions for the period 1/1/2020 – 31/12/2020 are fairly stated.

This statement shall be interpreted with the CO<sub>2</sub> equivalent assertion of Alexion Pharmaceuticals as a whole.

Note: This Statement is issued, on behalf of Client, by SGS United Kingdom Ltd, Rossmore Business Park, Inward Way, Ellesmere Port, Cheshire, CH65 3EN ("SGS") under its General Conditions for GHG Validation and Verification Services. The findings recorded hereon are based upon an audit performed by SGS. This Statement does not relieve Client from compliance with any bylaws, federal, national or regional acts and regulations or with any guidelines issued pursuant to such regulations. Stipulations to the contrary are not binding on SGS and SGS shall have no responsibility vis-à-vis parties other than its Client.